Author: Javelot, H; Straczek, C; Meyer, G; Gitahy Falcao Faria, C; Weiner, L; Drapier, D; Fakra, E; Fossati, P; Weibel, S; Dizet, S; Langrée, B; Masson, M; Gaillard, R; Leboyer, M; Llorca, PM; Hingray, C; Haffen, E
Title: Psychotropics and COVID-19: an analysis of safety and prophylaxis Cord-id: zj1w09vd Document date: 2021_9_2
ID: zj1w09vd
Snippet: The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes should be made to pharmacological treatments prescribed to mental health patients? Secondly, are there any positive side effects of these substances against SARS-CoV-2? Our aim was to analyze usage safety of psychotropics during COVID-19, therefore herein we have studied: (i) the risk of symptomatic complications of COVID-19 associated with the use of these drugs, notably c
Document: The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes should be made to pharmacological treatments prescribed to mental health patients? Secondly, are there any positive side effects of these substances against SARS-CoV-2? Our aim was to analyze usage safety of psychotropics during COVID-19, therefore herein we have studied: (i) the risk of symptomatic complications of COVID-19 associated with the use of these drugs, notably central nervous system activity depression, QTc interval enlargement and infectious and thromboembolic complications, (ii) the risk of mistaking the iatrogenic impact of psychotropics with COVID-19 symptoms, causing diagnostic error. Moreover, we provided a summary of the different information available today for these risks, categorized by mental health disorder, for the following: schizophrenia, bipolar disorder, anxiety disorder, ADHD, sleep disorders and suicidal risk. The matter of psychoactive substance use during the pandemic is also analyzed in this paper, and guideline websites and publications for psychotropic treatments in the context of COVID-19 are referenced during the text, so that changes on those guidelines and eventual interaction between psychotropics and COVID-19 treatment medication can be reported and studied. Finally, we also provide a literature review of the latest known antiviral properties of psychotropics against SARS-CoV-2 as complementary information.
Search related documents:
Co phrase search for related documents- abdominal pain and acute agitation: 1
- abdominal pain and acute episode: 1, 2
- abdominal pain and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71
- abdominal pain and acute infection patient: 1, 2
- abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- abdominal pain and acute symptom: 1, 2, 3, 4, 5
- abdominal pain and additional file: 1
- abdominal pain and liver pancreatic: 1, 2, 3, 4
- abdominal pain and long covid: 1, 2, 3, 4, 5, 6
- abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
- abdominal pain and low incidence: 1, 2, 3
- abdominal pain and low intensity: 1
Co phrase search for related documents, hyperlinks ordered by date